

BIOLOGICS, BIOSIMILARS & RHEUMATIC DISEASE



• About **54.4 million** Americans have arthritis.

BIOLOGICAL MEDICATIONS offer innovative treatment options.



BIOLOGICS:

Made from natural and living sources.
More complex than other drugs.

BIOSIMILARS:

Follow-on medicines. Similar to originator biologics with no clinically meaningful differences.

Of surveyed rheumatologists:



98% are familiar with biosimilars

90% feel comfortable prescribing biosimilars



The first rheumatology biosimilar was approved by the Food & Drug Administration in 2016.

Rheumatology treatments were among the first biosimilars ever approved.



12 TOTAL BIOSIMILARS are approved for:

- Rheumatoid Arthritis
- Juvenile Idiopathic Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Polyarticular Juvenile Idiopathic Arthritis
- Plaque Psoriasis

